These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 18480207)

  • 21. Natriuretic peptide testing for heart failure therapy guidance in the inpatient and outpatient setting.
    Green SM; Green JA; Januzzi JL
    Am J Ther; 2009; 16(2):171-7. PubMed ID: 19300043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role and assessment of ventricular peptides in heart failure.
    Winter WE; Elin RJ
    Clin Lab Med; 2004 Mar; 24(1):235-74. PubMed ID: 15157565
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Will the therapy of chronic heart failure be guided by plasma levels of natriuretic peptides?].
    Hradec J; Krupicka J; Janota T
    Cas Lek Cesk; 2009; 148(8):383-8. PubMed ID: 19899725
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood biomarker measurement as disease target: the case for generic treatment of high natriuretic peptide levels without a diagnosis of heart failure.
    Clark AL
    J R Coll Physicians Edinb; 2013; 43(2):99-100. PubMed ID: 23734347
    [No Abstract]   [Full Text] [Related]  

  • 25. Natriuretic peptide-guided management of patients with heart failure: a decade of progress but still a controversy.
    Baibars M; Ibrahim A; Fang JC; Sipahi I
    Future Cardiol; 2010 Nov; 6(6):743-7. PubMed ID: 21142628
    [No Abstract]   [Full Text] [Related]  

  • 26. [Clinical use of markers of neurohormonal activation in heart failure].
    Roig Minguell E
    Rev Esp Cardiol; 2004 Apr; 57(4):347-56. PubMed ID: 15104989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomarkers of extracellular matrix turnover.
    Zannad F; Pitt B
    Heart Fail Clin; 2009 Oct; 5(4):589-99. PubMed ID: 19631182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Role of natriuretic peptides in heart failure patients with special reference to those on cardiac resynchronization therapy.
    Ricciardi G; Pieragnoli P; Colella A; Giaccardi M; Padeletti L; Abbate R; Gensini GF; Michelucci A
    Minerva Cardioangiol; 2006 Dec; 54(6):743-52. PubMed ID: 17167386
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of biomarkers in the patient with heart failure.
    Chowdhury P; Kehl D; Choudhary R; Maisel A
    Curr Cardiol Rep; 2013 Jun; 15(6):372. PubMed ID: 23644993
    [TBL] [Abstract][Full Text] [Related]  

  • 30. C-terminal provasopressin (copeptin) is associated with left ventricular dysfunction, remodeling, and clinical heart failure in survivors of myocardial infarction.
    Kelly D; Squire IB; Khan SQ; Quinn P; Struck J; Morgenthaler NG; Davies JE; Ng LL
    J Card Fail; 2008 Nov; 14(9):739-45. PubMed ID: 18995178
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Natriuretic peptides in clinical practice].
    Urek R; Cubrilo-Turek M
    Acta Med Croatica; 2008 Feb; 62(1):53-6. PubMed ID: 18365500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk stratification and short-term prognosis in acute heart failure syndromes: a review of novel biomarkers.
    Avellino A; Collins SP; Fermann GJ
    Biomarkers; 2011 Aug; 16(5):379-92. PubMed ID: 21534728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natriuretic peptides and E-selectin as predictors of acute deterioration in patients with inotrope-dependent heart failure.
    Potapov EV; Hennig F; Wagner FD; Volk HD; Sodian R; Hausmann H; Lehmkuhl HB; Hetzer R
    Eur J Cardiothorac Surg; 2005 May; 27(5):899-905. PubMed ID: 15848333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Towards defining heart failure in adults with congenital heart disease.
    Bolger AP; Gatzoulis MA
    Int J Cardiol; 2004 Dec; 97 Suppl 1():15-23. PubMed ID: 15590075
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental biomarkers in heart failure: an update.
    Kobulnik J; Delgado D
    Expert Rev Cardiovasc Ther; 2012 Sep; 10(9):1119-32. PubMed ID: 23098148
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Low pulse pressure is independently related to elevated natriuretic peptides and increased mortality in advanced chronic heart failure.
    Voors AA; Petrie CJ; Petrie MC; Charlesworth A; Hillege HL; Zijlstra F; McMurray JJ; van Veldhuisen DJ
    Eur Heart J; 2005 Sep; 26(17):1759-64. PubMed ID: 15833758
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Biomarkers in heart failure: BNP and NT-proBNP].
    Ho CC; Liu CC
    Hu Li Za Zhi; 2009 Oct; 56(5):16-22. PubMed ID: 19760573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pleiotropic effects of atorvastatin in heart failure: role in oxidative stress, inflammation, endothelial function, and exercise capacity.
    Castro PF; Miranda R; Verdejo HE; Greig D; Gabrielli LA; Alcaino H; Chiong M; Bustos C; Garcia L; Mellado R; Vukasovic JL; Godoy I; Lavandero S
    J Heart Lung Transplant; 2008 Apr; 27(4):435-41. PubMed ID: 18374881
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Physiopathology of heart failure].
    Gomes MC; Ferreira A; Bettencourt P
    Rev Port Cardiol; 2004 May; 23 Suppl 2():II7-23. PubMed ID: 15222247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of soluble glycoprotein 130 and cardiac natriuretic peptides as long-term predictors of heart failure progression.
    Gwechenberger M; Pacher R; Berger R; Zorn G; Moser P; Stanek B; Huelsmann M
    J Heart Lung Transplant; 2005 Dec; 24(12):2190-5. PubMed ID: 16364870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.